Decentralized clinical trial for patients with advanced carcinomas helps determine their cancer’s response to specific drugs [EIN Presswire, July 19, 2022] xCures, Inc. is proud to announce their partnership with Travera, and the launch of a decentralized clinical trial that provides patients with advanced carcinoma a functional profile of their… Read more »


Technology To Beat Advanced Cancer
The xCures technology platform uses artificial intelligence (A.I.) and predictive modeling to identify and rank the most promising treatment options for people with cancer who have exhausted the standard of care.
For Patients
For Providers
Our DNA Is Patient-First Precision Oncology

At Cancer Commons we’ve helped thousands of patients with one-on-one research for the best treatment options. With xCures, we can help many, many more.
Erika Vial MonteverdiFormer Executive Director, Cancer Commons
“The program we ran on the xCures platform materially accelerated our development program of ONC201”
Wolfgang Oster MD, PhD
Founder Oncoceutics
Latest News
xCures and Novocure® partner to better understand quality of life in glioblastoma
Innovative collaboration focused on developing the first comprehensive Quality of Life dataset for glioblastoma patients [EIN PressWire June 21, 2022] xCures, Inc., is proud to announce their partnership with Novocure with the intent to develop the first comprehensive, longitudinal Quality of Life (QoL) dataset for glioblastoma (GBM) patients. The alliance… Read more »
xCures and Novocure® partner to better understand quality of life in glioblastoma
Innovative collaboration focused on developing the first comprehensive Quality of Life dataset for glioblastoma patients [EIN PressWire June 21, 2022] xCures, Inc., is proud to announce their partnership with Novocure with the intent to develop the first comprehensive, longitudinal Quality of Life (QoL) dataset for glioblastoma (GBM) patients. The alliance… Read more »